Patients with nasal polyps who receive dupilumab have a lower risk for using antibiotics or steroids early on than those ...

The weighted risks for major birth defects, spontaneous abortion and preterm delivery were not higher among pregnant women ...

Prospective registry study shows no increase in birth defects ...

Cutaneous T-cell lymphoma rates reverse course after 2015, prompting researchers to call for further study of biologic ...

For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

Mark Lebwohl, MD, discusses atopic march data and systemic treatment options for pediatric atopic dermatitis. Mark Lebwohl, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease Dupixent ...

The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier. In ...